Harnessing the Power of the Innate Immunity to Fight Solid Tumor
Time: 12:15 pm
day: Conference Day One - Track A
Details:
- Developing off-the-shelf allogeneic healthy donor-derived γδ T cell therapy for solid tumor
- Polyclonal, natural composition of γδ T cell subsets, leveraging the non-redundant functions of diverse subsets
- Armed and engineered dual CAR targets tumor and immunesupporessive stroma in the TME to optimize anti-tumor potency
- Gene editing to overcome immune suppression in the solid tumor TME
